Printer Friendly

THE QUIGLEY CORPORATION: DURATION OF COMMON COLD SHORTENED WITH PATENTED PRODUCT

 THE QUIGLEY CORPORATION: DURATION OF COMMON COLD
 SHORTENED WITH PATENTED PRODUCT
 DOYLESTOWN, Pa., June 1 /PRNewswire/ -- The Quigley Corporation (OTC: Pink Sheets) announced today that on May 4, 1992, it signed an exclusive agreement for the worldwide marketing rights of a zinc gluconate/glycine lozenge formulation, developed by John C. Godfrey, Ph.D., patented in the United States, United Kingdom, Sweden, France, Italy, Canada, Germany and pending in Japan.
 Under an FDA-approved Investigational New Drug Application filed by Dartmouth College, a randomized double-blind placebo-controlled study conducted at Dartmouth College Health Service, Hanover, N.H., concluded that the zinc gluconate/glycine lozenge formulation treatment, initiated within 48 hours of symptom onset, resulted in a 42 percent reduction in the total duration of the common cold.
 On May 22, 1992, "Zinc and the Common Cold, a Controlled Clinical Study," by Dr. Godfrey, et al., was published in England, in the Journal of International Medical Research (Vol. 20, No. 3, Pgs. 234-246).
 According to Godfrey, flavorings used in other zinc lozenge products (citrate, tartrate, aspartate, orotate, picolinate, mannitol or sorbitol) render the zinc inactive and unavailable to the patient's nasal passages, mouth and throat, where cold symptoms have to be treated.
 This new, patented pleasant-tasting formulation delivers 93 percent of the active zinc to the mucosal surfaces, Godfrey said. The patient has the same sequence of symptoms as in the absence of treatment, but goes through the phases at a much accelerated rate and with reduced symptom severity.
 A further interesting application of the formulation, he said, will be its use in chewing gum.
 The introduction of a zinc gluconate/glycine lozenge objectifies the stance The Quigley Corporation has taken in focusing upon natural health and nutrition-oriented products. The company said it currently distributes its unique "Quigley's Alpha 1 Nutri-Bar," an all-natural, easily digestible, high-energy nutritional product, finding wide acceptability with the consumer ranging from sporting enthusiasts to diabetics.
 The company's advisory board consists of academe and professional sports figures and is chaired by Robert L. Pollack, Ph.D., director of research and development and professor emeritus, department of biochemistry, Temple University School of Medicine. Godfrey, along with his wife Nancy Jane Godfrey, Ph.D., have joined the company's advisory board.
 /delval/
 -0- 6/1/92
 /CONTACT: Guy Quigley or Charles Phillips of The Quigley Corporation, 215-766-2064/ CO: The Quigley Corporation ST: Pennsylvania, New Hampshire IN: MTC SU: PDT


MK-LJ -- PH004 -- 5492 06/01/92 08:04 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 1, 1992
Words:405
Previous Article:OHM CORPORATION'S MINNESOTA OFFICE MOVES
Next Article:HAYES AND ROCKWELL REACH AGREEMENT ON SUPPORT FOR INDUSTRY STANDARD ESCAPE SEQUENCE
Topics:


Related Articles
Quigley Corporation Announces Acquisition Of Cold-Relief Use Patent
The Quigley Corporation Launches National TV Advertising Campaign; Cold-Eeze(R) Reported as the Hottest Selling Cold Remedy in the United States
The Quigley Corporation Comments on News Story Touting a Zinc Spray That Shortens the Common Cold.
The Quigley Corporation Brings Suit Against GumTech International For Patent Infringement.
Former FTC Associate Director Says FTC Leaves COLD-EEZE(R) Core Claim Untouched.
The Quigley Corporation, Maker of COLD-EEZE(R), Announces Ruling in Patent Infringement Suit.
The Quigley Corporation Initiates Cold-Eeze(R) 'Have Always Been PPA-free' Ads.
Second Heritage School Study Confirms COLD-EEZE(R) Lozenges as Effective Common Cold Treatment in Adolescent Population.
Independent Study Finds That Daily Dose of COLD-EEZE(R) Cuts the Chances of Catching a Cold By More Than 50%.
U.S. Centers for Disease Control Approves Partnership Agreement With The Quigley Corporation.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters